Stablix is at the forefront of developing targeted deubiquitination therapeutics (TDT), a novel approach aimed at addressing diseases linked to aberrant ubiquitination. This process can lead to excessive protein degradation, mislocalization of proteins, and inappropriate activation of cellular pathways, all of which contribute to various health issues. Stablix's innovative strategy involves the use of heterobifunctional small molecules that selectively recruit active deubiquitinases (DUBs) to target proteins, effectively removing ubiquitin and restoring normal protein function. By leveraging the body's own cellular mechanisms, Stablix aims to create transformative medicines for conditions such as cancer, rare diseases, and immunological disorders.

The company's platform is built on the understanding that ubiquitin plays a critical role in regulating protein lifecycle and activity, influencing both degradation and signaling processes. Stablix's multidisciplinary team combines expertise in drug discovery and development to create a powerful therapeutic modality that addresses the underlying causes of disease through targeted deubiquitination. This approach not only aims to restore deficient proteins to therapeutic levels but also seeks to reestablish normal cellular functions, thereby offering new hope for patients with unmet medical needs.

United States

Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. Co-located in New York City and Boston, we are a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way we approach drug development by establishing a powerful small-molecule modality for a wide variety of devastating diseases.

Stablix

Company Details